当前位置：
X-MOL 学术
›
Lancet Diabetes Endocrinol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2022-05-18 , DOI: 10.1016/s2213-8587(22)00135-8 Maria Fleseriu 1 , Frederic Castinetti 2 , Mônica Gadelha 3 , Andrea Giustina 4 , André Lacroix 5 , Shlomo Melmed 6 , John Newell-Price 7 , Rosario Pivonello 8 , Martin Reincke 9 , Beverly M K Biller 10 ,
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2022-05-18 , DOI: 10.1016/s2213-8587(22)00135-8 Maria Fleseriu 1 , Frederic Castinetti 2 , Mônica Gadelha 3 , Andrea Giustina 4 , André Lacroix 5 , Shlomo Melmed 6 , John Newell-Price 7 , Rosario Pivonello 8 , Martin Reincke 9 , Beverly M K Biller 10 ,
Affiliation
Abstract not available
中文翻译：
Osilodrostat 用于治疗库欣病：疗效、稳定性和持久性 – 作者的回复
摘要不可用
更新日期：2022-05-20
中文翻译：
Osilodrostat 用于治疗库欣病：疗效、稳定性和持久性 – 作者的回复
摘要不可用
京公网安备 11010802027423号